US Material Events SEC 8-K Filings — July 07, 2026

07-07-2026

Kingfish Holding Corp disclosed that Director Lori M. Toomey will not stand for re-election at the 2027 annual meeting, and that the Toomey Directors will not extend or renew the $365,000 Toomey Loan (plus ~$9,191 accrued interest) maturing December 31, 2026. The company faces significant liquidity risk as it may need to seek alternative funding sources to repay the loan, and is also a guarantor on the $1,519,179 Hancock Whitney Loan with a 6.735% interest rate, which is senior secured on all company assets.

• · Lori M. Toomey's decision not to stand for re-election was not due to any dispute with the company or Board.
• · The Toomey Loan is secured by all assets of the company.
• · The Toomey Directors have not indicated any intent to modify or cease other Renovo Loans.
• · The Hancock Whitney Loan is senior secured on all assets of the Company and 6 LLC, and the Company is a guarantor.
• · Lease payments from the Company to 6 LLC are the source of funds for 6 LLC to repay Hancock Whitney Loan.
• · Controlling equity holders of 6 LLC include the Toomey Directors, Randall M. Moritz, and Keri A. Moritz.

07-07-2026

MasTec, Inc. and its subsidiary MasTec North America, Inc. entered into a Term Loan Agreement on July 7, 2026, with Bank of America as Administrative Agent and several other lenders, establishing two term loan facilities (Three-Year and Four-Year). The agreement includes customary representations, covenants (including a Consolidated Leverage Ratio covenant), events of default, and provisions for interest rates based on the Company's leverage ratio and debt ratings. No specific dollar amounts for the facilities are disclosed in the filing excerpt.

• · The agreement includes a Consolidated Leverage Ratio negative covenant (Section 7.09).
• · Interest rates are determined by a grid referencing the Company's Consolidated Leverage Ratio and Debt Ratings from S&P and Moody's, with a mechanism to resolve splits between the two.
• · The agreement provides for joint and several liability of the two borrowers (Section 2.14).
• · The filing includes exhibits such as forms of Loan Notice, Note, Compliance Certificate, Assignment and Assumption, and Solvency Certificate.

07-07-2026

The Children's Place, Inc. appointed Muhammad Asif Seemab as President and Interim Chief Executive Officer effective July 6, 2026, replacing his prior role as Executive Vice Chairman. The offer letter includes an annual base salary of $497,500 but notably excludes participation in the annual management incentive plan and equity incentive plan, and explicitly denies severance or separation benefits unless otherwise approved by the Board. The appointment is interim until a permanent CEO is identified, and the letter includes a 12-month non-compete clause covering major competitors.

• · Mr. Seemab will not receive any additional compensation for his continued service as a Board member while an executive.
• · The offer letter explicitly states employment is at-will and does not constitute an employment contract.
• · Mr. Seemab is subject to stock ownership guidelines adopted by the Compensation Committee.
• · The non-compete clause specifically lists major retailers and apparel companies as competitive businesses.
• · Mr. Seemab acknowledged he is a 'senior executive' under the FTC's Non-Compete Clause Rule.

07-07-2026

21Shares Dogecoin ETF (TDOG) announced the termination of its pricing benchmark licensing agreement with CF Benchmarks, effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited on or about August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change does not involve any financial figures or performance metrics, and no positive or negative financial impact is disclosed.

• · The Pricing Benchmark Licensing Agreement has a one-year initial term and automatically renews for successive one-year periods unless terminated.
• · The new FTSE licensing agreement is expected to have a one-year initial term and will automatically renew for successive one-year periods unless terminated.
• · FTSE is a company incorporated and registered in England, with principal offices at 10 Paternoster Square, London, EC4M 7LS, United Kingdom.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.

07-07-2026

On July 1, 2026, James D. Burnham resigned from the Board of Directors of RenX Enterprises Corp. (formerly Safe & Green Development Corp) and was immediately hired as Director of Growth & M&A under a one-year employment agreement with an annual base salary of $275,000 and a discretionary bonus of up to 15% of base salary. The resignation was not due to any disagreement with the company, and the new role focuses on operations, business development, and M&A, including deployment of the Microtec UTM 1200 Mill.

• · James Burnham's son, Tristan Burnham, is employed as Vice President of Operations at the company's subsidiary, Resource Group US Holdings LLC.
• · The employment agreement explicitly states that Burnham is not an executive officer and is not entitled to any equity awards unless separately approved by the Board.
• · The prior consulting agreement with JDB Consulting Services, Inc. (dated June 2, 2025) was terminated effective July 1, 2026.
• · Burnham's key responsibilities include leading the deployment and commissioning of the Microtec UTM 1200 Mill, including capital expenditure management and operator training.

07-07-2026

On June 30, 2026, CleanCore Solutions, Inc. (ZONE) entered into a Side Letter Agreement and RSU Agreement with CFO David J. Enholm, reducing his annual base salary from $75,000 to $62,400 effective July 1, 2026, at his voluntary request. In consideration, the Company granted him 80,000 restricted stock units (RSUs) under the 2022 Equity Incentive Plan, with 40,000 vesting immediately on July 1, 2026, and 40,000 vesting upon the filing of the Annual Report on Form 10-K for FY2026. The agreements include clawback and forfeiture provisions tied to potential misstatements or SEC inquiries.

• · The salary reduction was voluntary and at Mr. Enholm's request, and he waived any claim of breach or 'good reason' for resignation.
• · Mr. Enholm also waived all rights to cash payment for accrued or unused paid time off upon future termination.
• · Unvested RSUs accelerate upon death, disability, retirement, or termination without cause; otherwise forfeited.
• · Clawback provisions allow the Compensation Committee to suspend, cancel, or recoup RSUs if the Form 10-K contains material misstatements or becomes subject to SEC inquiry, with at least 15 business days' notice to Mr. Enholm.

07-07-2026

Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals for $85 per share in cash, totaling approximately $10 billion ($8.8 billion net of cash). The deal adds potential best-in-class endocrinology assets including PALSONIFY (approved once-daily oral for acromegaly, launched October 2025 with strong early uptake) and atumelnant (Phase 3 for congenital adrenal hyperplasia). Vertex expects the acquisition to accelerate revenue growth and support sustained double-digit growth, with the transaction becoming accretive to non-GAAP operating income in 2029. However, the deal carries integration risks, requires regulatory and stockholder approvals, and the pipeline assets remain subject to clinical and commercial uncertainties.

• · PALSONIFY is FDA and EMA approved; U.S. launch occurred in October 2025.
• · Atumelnant is in Phase 3 for adults and Phase 2/3 for pediatric CAH, and Phase 2 for ACTH-dependent Cushing's syndrome.
• · Crinetics has IP protection into the 2040s.
• · Crinetics was founded in 2008 and is headquartered in San Diego, CA.
• · Only ~40-50% of acromegaly patients achieve durable remission with surgery.
• · Only 18% of patients remain on injectable SRLs at ~3 years, indicating high discontinuation.
• · PALSONIFY is indicated for both treatment-naïve and switch patients.
• · Vertex expects the transaction to be accretive to non-GAAP operating income in 2029.
• · The acquisition is supported by fully committed bridge financing.

07-07-2026

FortuneX Acquisition Corporation entered into Amendment No. 1 to its Underwriting Agreement on July 1, 2026, revising terms related to its IPO, including firm and option units, deferred underwriting discount, private placement units, and administrative services. The amendment involves Polaris Advisory Partners (representative of the underwriters) and Kingswood Capital Partners LLC. No financial figures or performance metrics were disclosed in this filing.

• · Amendment No. 1 to the Underwriting Agreement was dated July 1, 2026, and filed as Exhibit 10.1.
• · The original Underwriting Agreement was dated May 21, 2026.
• · The amendment revises provisions regarding Firm Units, Option Units, deferred underwriting discount, private placement units, administrative services, offering expenses, Representative's right of first refusal, and trust account acknowledgements.
• · The filing includes a Cover Page Interactive Data File (Inline XBRL).

07-07-2026

Purple Innovation, Inc. (PRPL) held a Special Meeting on July 2, 2026, where stockholders approved a reverse stock split (ratio 1-for-10 to 1-for-30) and an adjournment proposal. Subsequently, on July 4, 2026, the Board amended CEO Robert T. DeMartini's employment agreement to provide a $1,000,000 retention bonus vesting in three tranches through June 2027 and enhanced retirement vesting provisions for equity awards. The reverse stock split aims to maintain Nasdaq listing compliance, while the CEO retention package aligns leadership incentives with shareholder interests.

• · The reverse stock split ratio will be determined by the Board between 1-for-10 and 1-for-30.
• · The retention bonus vests 10% on Oct 31, 2026, 20% on Feb 28, 2027, and 70% on Jun 30, 2027.
• · If CEO is terminated without cause or resigns for good reason after a change in control, the entire unpaid retention bonus becomes payable.
• · Enhanced retirement provisions allow time-based RSUs to vest as if CEO remained employed for 12 additional months, and PSUs to vest pro-rata based on actual performance.
• · The retirement provisions require CEO to give at least six months' advisory notice and retire on a date agreed with the Board.
• · All compensation is subject to clawback policies and continued compliance with employment agreement covenants.

07-07-2026

Quantum Cyber N.V. (formerly Mainz Biomed N.V.) disclosed the appointment of Peter O'Rourke as President of its wholly owned subsidiary Quantum Drones Corp., effective July 1, 2026, with a monthly base salary of $20,833.33 (reduced to $16,666.67 for the remainder of 2026 due to prior director compensation) and stock options for 112,859 ordinary shares at $1.45 per share. Additionally, Louis Buffalino was appointed as an independent director and to the Audit, Compensation, and Nominating and Corporate Governance Committees, effective July 1, 2026. The filing reflects a shift in focus from the company's former pharmaceutical operations to drone manufacturing, but no financial performance data is provided.

• · Louis Buffalino previously served as Senior Vice President at Cushman & Wakefield (2012-2024) and chaired the Nominating and Governance Committee at Blink Charging Inc. (2019-2024).
• · O'Rourke's principal work location is 10232 Brittenford Dr., Vienna, VA 22182, with a role at the Company's Bridgeport, Connecticut factory.
• · The employment agreement includes customary non-competition, non-solicitation, and non-disparagement provisions.
• · Severance upon termination without cause is one month of base salary continuation plus accrued obligations.
• · The company changed its name from Mainz Biomed N.V. to Quantum Cyber N.V. in November 2021.

07-07-2026

Vroom, Inc. announced an amendment to its warehouse credit facility on June 30, 2026. The amendment extends the commitment termination date from July 2, 2026 to June 2, 2027, and modifies financial covenants, including increasing the maximum permitted leverage ratio and maximum advance rate, while simplifying the minimum tangible net worth threshold. In connection with this amendment, Vroom Finance Holdings LLC entered into a performance guaranty for obligations under the facility.

• · Amendment No. 29 modifies the warehouse credit facility originally dated November 19, 2013.
• · The amendment increases the maximum permitted leverage ratio and the maximum advance rate.
• · The minimum tangible net worth threshold is simplified and reduced.
• · The performance trigger framework has been updated.
• · Vroom Finance Holdings LLC provided a Performance Guaranty for the facility obligations.

07-07-2026

Solstice Advanced Materials Inc. (Parent) has entered into a definitive Agreement and Plan of Merger to acquire Element Solutions Inc (Company) through a two-step merger process structured as a tax-free reorganization under Section 368(a) of the Code. The transaction will be effected via a first merger of a wholly-owned subsidiary into Element Solutions, followed immediately by a second merger into another subsidiary, with Element Solutions stockholders receiving Parent stock and three designated Company directors joining the Parent board. The closing is conditioned on stockholder approvals, regulatory clearances, and other customary conditions, with a potential delay option for Parent if conditions are satisfied after December 6, 2026.

• · The merger is structured as two sequential mergers: first Merger Sub One merges into Element Solutions, then the surviving corporation merges into Merger Sub Two.
• · The transaction is intended to qualify as a tax-free reorganization under Section 368(a) of the Code.
• · Parent may delay the closing until January 4, 2027, if the closing condition satisfaction date occurs after December 6, 2026 and before January 1, 2027.
• · Three Designated Directors from Element Solutions' board will join the Parent board of directors (expanded to 11 members) as of the First Merger Effective Time.
• · Concurrently with the agreement, certain Element Solutions stockholders entered into a Voting and Support Agreement in favor of Parent.
• · The agreement includes customary representations, warranties, covenants, and conditions precedent for both parties, including no material adverse effect clauses.

07-07-2026

MeiraGTx announced a strategic investment of up to $400 million from Oberland Capital, comprising up to $375 million in non-dilutive royalty funding and up to $25 million in equity. The initial $135 million funded includes $125 million for low single-digit capped royalties on three late-stage programs (AAV2-hAQP1, bota-vec, AAV-AIPL1) and a $10 million equity investment, with additional tranches tied to data readouts and regulatory approvals through 2028. While the deal provides substantial non-dilutive capital to support commercialization, the royalty payments are capped at a multiple of funded amounts, and the company remains in a clinical-stage, pre-revenue position with significant ongoing risks.

• · Royalty payments are capped at a multiple of the amounts funded.
• · The agreement includes flexible provisions for potential change of control, with the ability for MeiraGTx to buy back the entire funded royalty note at any time by paying certain specified amounts.
• · Oberland Capital has the right to purchase an additional $15 million in equity in MeiraGTx.
• · MeiraGTx has four late-stage clinical programs, including one for Parkinson's disease.
• · MeiraGTx has developed a proprietary riboswitch gene regulation technology for in vivo delivery of biologic therapeutics using oral small molecules.

07-07-2026

Vivani Medical announced a non-exclusive agreement with Novo Nordisk to evaluate NPM-139, its semaglutide implant for chronic weight management. The agreement has no exclusivity provisions for NPM-139 or Vivani's NanoPortal technology. Separately, Vivani expects to initiate a Phase 1 first-in-human study of NPM-139 in mid-2026, with Wegovy as an active comparator. While the partnership signals Novo Nordisk's interest, the non-exclusive nature limits immediate financial upside, and the Phase 1 study has yet to begin.

• · The agreement is non-exclusive with no exclusivity provisions for NPM-139 or NanoPortal technology.
• · Phase 1 study expected to start mid-2026, with Wegovy as active comparator.
• · Study objectives include safety, pharmacokinetics, and tolerability to support Phase 2 dose-ranging study.
• · Vivani's NanoPortal implants aim for once- or twice-yearly dosing with ability to stop treatment if needed.

07-07-2026

Upland Software disclosed the retirement of CFO Michael D. Hill effective July 27, 2026, and the appointment of David Tamez as interim CFO, effective the same day. The company has initiated a search for a permanent successor, and Mr. Hill’s departure is stated to be amicable. Mr. Tamez has been with Upland since 2014, most recently as SVP of Treasury Management. No compensation details for the interim role have been finalized yet.

• · Mr. Hill’s retirement date is July 27, 2026; he notified the board on June 30, 2026.
• · The board appointed David Tamez as interim CFO on July 6, 2026, effective July 27, 2026.
• · David Tamez has served as Senior Vice President, Treasury Management since June 2023; prior roles include VP, Accounting and Corporate Controller (2014–2023).
• · No family relationships exist between Mr. Tamez and any director or executive officer.
• · Compensation for the interim CFO role has not yet been determined; an amendment to the 8-K will be filed once finalized.

07-07-2026

Vor Biopharma Inc. announced the resignation of director Andrew Levin, M.D., Ph.D., effective July 6, 2026, with no disagreement cited. The company appointed David Zaccardelli, Pharm.D., as an independent Class II director to fill the vacancy, effective July 7, 2026. Dr. Zaccardelli brings extensive pharmaceutical leadership experience, including prior CEO roles at Verona Pharma (acquired by Merck in 2025) and Dova Pharmaceuticals (acquired by Sobi in 2019).

• · Dr. Zaccardelli has not been appointed to any Board committee as of the filing date.
• · Dr. Zaccardelli will enter into the company's standard form of indemnification agreement.
• · The initial stock option grant is for the lesser of 68,000 shares or $700,000 in aggregate grant date fair value.
• · The annual stock option grant is for the lesser of 34,000 shares or $350,000 in aggregate grant date fair value, beginning with the 2027 annual stockholder meeting.

07-07-2026

Frontier Group Holdings, Inc. entered into a definitive agreement with Avolon to sell 11 A321neo aircraft from its existing purchase commitment as part of a fleet-rightsizing initiative. The sale includes 3 deliveries expected in Q4 2026 and 8 in the first half of 2027, with aircraft sold at current market rates factoring in transition costs. As a result, Frontier now expects to take delivery of 22 aircraft in 2026 (8 A320neo and 14 A321neo, with 3 of the A321neo sold) and exit the year with a fleet of 171 aircraft.

• · The agreement was previously disclosed as a non-binding agreement in principle on May 5, 2026.
• · The aircraft are sold at current market rates factoring in transition-related costs, including estimated remarketing costs.
• · Each aircraft will be sold at the time of delivery to the Company.

07-07-2026

Fiserv President Dhivya Suryadevara resigned for 'good reason' effective July 7, 2026, and will remain a non-executive employee through July 31, 2026, for transition. Andrew Gelb and Srini Krish were appointed as interim leaders of the Financial Solutions business. The departure of a key executive introduces leadership uncertainty, though the company has named internal successors.

• · Suryadevara's resignation is for 'good reason' under her August 28, 2025 offer letter and the Fiserv Executive Severance and Change of Control Policy.
• · She will remain a non-executive officer employee through July 31, 2026, receiving base salary and benefits during transition.
• · Andrew Gelb joined Fiserv in 2014 and has held senior roles including longtime head of issuer solutions.
• · Srini Krish joined Fiserv in 2014 and previously served as global Chief Information Officer.

07-07-2026

Jack in the Box Inc. filed its annual report for the fiscal year ended September 28, 2025, reporting net earnings of $127,000,000, down 9.3% year-over-year from $140,000,000. Same-store sales declined 1.5% system-wide, with company-operated stores down 2.1% and franchise stores down 1.3%. However, total revenues increased 2.1% to $1,633,500,000, driven by franchise royalty and occupancy revenue growth.

• · Franchise revenue grew 3.0% to $1,020,000,000, partially offsetting company-operated revenue decline of 0.5% to $613,500,000
• · Restaurant-level EBITDA margin contracted 120 basis points to 22.4% from 23.6%
• · General and administrative expenses increased 4.7% to $217,000,000 due to higher compensation costs
• · Company repurchased $50,000,000 of common stock during the year, down from $75,000,000 in FY 2024
• · Capital expenditures totaled $85,000,000, primarily for restaurant remodels and technology upgrades
• · Free cash flow decreased 15.0% to $110,000,000 from $129,400,000

07-07-2026

Yext, Inc. expanded its board from seven to eight directors and elected Cynthia Paul as a Class I member, effective July 7, 2026. Ms. Paul, founder and CEO of Lynrock Lake LP, brings extensive investment and board experience. She received an initial RSU grant valued at $350,000 (89,058 units) vesting over three years, and is eligible for standard director compensation.

• · Cynthia Paul's term expires at the 2027 annual meeting of stockholders.
• · Ms. Paul served on the board of Allot Ltd. from December 2022 to June 2026, ON24, Inc. from March 2023 until its sale in April 2026, and DSP Group, Inc. from April 2018 until its sale in December 2021.
• · Ms. Paul graduated from Princeton University in 1994 with an Independent Major in Statistics and Operations Research, a Certificate from the Princeton School of Public and International Affairs, and a Certificate in Engineering Management Systems.
• · The initial RSU grant vests in approximately equal annual installments over three years, subject to continued service.
• · Annual director equity grants vest 100% on the one-year anniversary or upon a change of control.

07-07-2026

VSee Health, Inc. entered into a Securities Purchase Agreement with ClearThink Capital Partners, LLC on June 17, 2026, issuing a promissory note with an aggregate principal amount of $280,000 (including a $30,000 original issue discount) in exchange for net proceeds of $250,000. The note is convertible into common shares (par value $0.0001 per share) and is being sold in reliance on an exemption from registration under the Securities Act. The company has 47,299,421 shares outstanding out of 100,000,000 authorized shares, and no material adverse changes have been reported since December 31, 2025.

• · The securities are being sold under an exemption from registration under the Securities Act of 1933, relying on Regulation D accredited investor rules.
• · The note bears a restrictive legend and can only be transferred under an effective registration statement or with a legal opinion acceptable to the company.
• · The company represents that it has filed all required SEC reports and that its financial statements comply with GAAP.
• · No material adverse change has occurred since December 31, 2025, according to the company's representation.
• · The company is not an investment company under the Investment Company Act of 1940.

07-07-2026

StageWise Strategies Corp. entered into a Share Subscription Agreement with its controlling shareholder Jakhongir Abidovich Artikkhodjaev, who currently owns approximately 74.2% of the company, to issue 1,000,000 shares of common stock for an aggregate purchase price of $250,000. A partial payment of $44,500 was received on June 30, 2026, with the remaining $205,500 expected by July 31, 2026. The transaction is a private placement exempt from registration under Section 4(a)(2) of the Securities Act, and the shares will be restricted securities.

• · The subscriber is a controlling shareholder owning approximately 74.2% of the company prior to the issuance.
• · The shares are restricted securities under Rule 144(a)(3) and will bear a restrictive legend.
• · The subscriber represented that he is an accredited investor and is acquiring the shares for investment purposes.
• · No broker, finder, or other financial consultant acted on behalf of either party in connection with the agreement.
• · The agreement is governed by the laws of the State of Nevada.

07-07-2026

Four Leaf Acquisition Corp (FORLW) announced a comprehensive governance restructuring, with the resignation of three directors (Alvin Wang, Stephen Markscheid, Rahul Mewawalla) and CFO Coco Kou, effective July 7, 2026. The company appointed Nanuk Warman, Jay Izso, and Mark DiSabato as independent directors, and Greg McCraw as the new CFO. The resignations were not due to any disagreements with the company.

• · The company moved its headquarters to 600 Park Offices Drive, Suite 300-4133, Durham, NC 27713 and updated its telephone number to 919-526-1070.
• · Nanuk Warman is CFO of CitroTech, Inc. (NYSE: CITR) and holds CPA and CFA designations.
• · Mark DiSabato has over 22 years of experience in governance, risk, and compliance including roles at National Bank of Egypt, Citi, Deutsche Bank, and Shutterstock.
• · Greg McCraw has served as CFO of Data443 Data Risk Mitigation, Inc. since September 2022.

07-07-2026

Expion360 Inc. (XPON) announced on July 7, 2026 that COO Carson Heagen resigned effective August 1, 2026 for personal reasons. The departure of a key operations executive introduces leadership uncertainty, though the company has not disclosed a replacement or interim plan.

• · Resignation effective August 1, 2026
• · No replacement or interim COO announced
• · Company is an emerging growth company

07-07-2026

Genworth Financial announced that President & CEO Thomas J. McInerney is taking a temporary leave of absence to focus on his health. CFO Jerome Upton has been named Interim President & CEO, effective immediately. The Board expressed confidence in the leadership team's ability to execute the existing strategy and maintain continuity during this period.

• · Tom McInerney joined Genworth as President and CEO in January 2013.
• · Jerome Upton has been with the company since 1998 and served as CFO since March 2023.
• · Genworth is the majority owner of Enact Holdings, Inc. (Nasdaq: ACT).

07-07-2026

CalciMedica, Inc. appointed Evgeny Zaytsev, M.D., Ph.D. as a Class I director, effective July 2, 2026, increasing the board size from seven to eight directors. Concurrently, Fred Middleton informed the board of his intention to retire at the 2026 annual meeting, after which the board will revert to seven directors. Dr. Zaytsev will receive a $40,000 annual cash retainer and an option to purchase 20,000 shares vesting over three years.

• · Dr. Zaytsev's appointment is effective immediately, with a term expiring at the 2027 annual meeting.
• · There are no arrangements or understandings with any other person regarding his selection as a director.
• · No transactions requiring disclosure under Item 404(a) of Regulation S-K exist involving Dr. Zaytsev.
• · The option to purchase 20,000 shares vests monthly over three years from July 2, 2026, subject to continuous service.
• · Fred Middleton's retirement is not due to any disagreement with the company.

07-07-2026

RPC Inc. entered into an amended and restated credit agreement dated June 30, 2026, with Bank of America as administrative agent, Truist Bank and PNC Bank as co-syndication agents, and other lenders, replacing the existing credit agreement from August 31, 2010. The new agreement provides for a revolving credit facility with pricing based on the company's consolidated leverage ratio, with commitment fees ranging from 0.200% to 0.300% and interest spreads from 1.250% to 2.250% for Term SOFR loans plus letters of credit. Specific aggregate commitment amounts are not disclosed in the filing excerpt.

• · The agreement amends and restates the existing credit agreement dated August 31, 2010.
• · The credit facility includes revolving loans, swing line loans, and letters of credit.
• · Advance limits are subject to a borrowing base calculation during periods when Consolidated EBITDA is less than $50 million.
• · The total aggregate commitments are not specified in this filing excerpt; the schedule of commitments (Schedule 2.01) is referenced but not included.
• · Pricing is determined by a five-level grid based on the Consolidated Leverage Ratio, with an initial Pricing Level 1 applied until delivery of the compliance certificate for the quarter ending June 30, 2026.

07-07-2026

LifeStance Health Group, Inc. (LFST) announced the resignation of director Jeffrey Rhodes effective July 2, 2026, with no disagreement cited. On the same day, the Board appointed three new directors: Thurman Justice, Lori Goltermann (both as Class II directors, term until 2029 annual meeting), and Safwan Shabab (Class III director, term until 2027 meeting). The new directors bring committee assignments and, for Justice and Goltermann, initial equity grants.

• · Mr. Shabab was appointed in accordance with a Stockholder's Agreement dated June 9, 2021.
• · The initial RSU awards to Justice and Goltermann (35,492 each) are subject to continued service on the Board.
• · Jeffrey Rhodes' resignation was effective immediately and not due to any disagreement with the Company.

07-07-2026

ARS Pharmaceuticals, Inc. announced the termination of CEO Richard Lowenthal without cause, effective immediately, and the appointment of President Donn Casale as the new CEO and Class III director. The change is effective July 7, 2026, with Mr. Casale serving until the 2029 annual meeting.

• · Richard Lowenthal's termination was without cause, effective immediately as of July 6, 2026.
• · Donn Casale was appointed to the Board as a Class III director, with a term expiring at the 2029 annual meeting.
• · Mr. Casale's biographical details are incorporated by reference from the May 13, 2026 Form 8-K.

07-07-2026

Quaker Chemical Corporation (Quaker Houghton) announced the resignation of Steven Dassing as Vice President, Corporate Controller and Principal Accounting Officer, effective July 22, 2026, to pursue another career opportunity. The departure is not due to any dispute with the company. Upon his resignation, Executive Vice President and CFO Mr. Coler (age 53) will assume the additional role of Principal Accounting Officer without any new compensatory arrangements.

• · Resignation effective date: July 22, 2026.
• · Mr. Coler's biographical information is referenced from the 2025 Annual Report on Form 10-K filed February 23, 2026.
• · No new compensatory arrangements for Mr. Coler in connection with the additional role.
• · No arrangements or understandings with any other person regarding Mr. Coler's selection as officer.
• · No family relationships between Mr. Coler and any director or executive officer.
• · Mr. Coler has no direct or indirect material interest in any existing or proposed transaction requiring disclosure under Item 404(a) of Regulation S-K.

07-07-2026

The ONE Group Hospitality, Inc. dismissed Deloitte & Touche LLP as its independent auditor and engaged Grant Thornton LLP, effective June 30, 2026, following a competitive selection process for the fiscal year ending December 27, 2026. Deloitte's reports for fiscal years 2024 and 2025 contained no adverse opinions or qualifications, and there were no disagreements or reportable events during those periods or the subsequent interim period. The change appears orderly and without any accounting disputes.

• · Deloitte's reports on the Company's consolidated financial statements for fiscal years ended December 28, 2025 and December 31, 2024 did not contain any adverse opinion, disclaimer of opinion, or qualification.
• · No disagreements or reportable events occurred during the fiscal years ended December 28, 2025 and December 31, 2024, or the subsequent interim period through June 30, 2026.
• · The Company had not consulted Grant Thornton on any accounting, auditing, or financial reporting matters prior to engagement.
• · The Audit Committee conducted a competitive process to select the new auditor.

07-07-2026

21Shares Sui ETF (TSUI) is terminating its benchmark licensing agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a broader transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited (FTSE) on or about August 24, 2026, to use FTSE index data for the Trust. This change in benchmark provider may introduce operational and valuation adjustments, but no financial impact or performance data is disclosed.

• · The Pricing Benchmark Licensing Agreement with CF Benchmarks has a one-year initial term and auto-renews unless terminated.
• · The new FTSE license is expected to have a one-year initial term with automatic renewal.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.
• · The termination notice was provided on June 30, 2026, with an effective date of August 31, 2026.

07-07-2026

21Shares Polkadot ETF (TDOT) is terminating its benchmark licensing agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change is a strategic shift in benchmark provider but does not involve any financial terms or performance data.

• · Termination notice was provided on June 30, 2026, with the agreement ending August 31, 2026.
• · The new FTSE licensing agreement is expected to have a one-year initial term with automatic renewal.
• · FTSE is experienced in digital asset indices and is unaffiliated with the sponsor.

07-07-2026

The 21Shares Solana ETF (TSOL) filed an 8-K on July 7, 2026, announcing the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks, effective August 31, 2026. The sponsor plans to replace it with a new licensing agreement with FTSE International Limited, expected to be in place by August 24, 2026, marking a benchmark provider transition. No financial figures were disclosed in this filing, and there is no indication of any negative impact; rather, the move suggests a strategic operational update.

• · The Pricing Benchmark Licensing Agreement had a one-year initial term with automatic renewals.
• · CF Benchmarks is unaffiliated with the sponsor.
• · The new FTSE agreement is expected to have a one-year initial term and automatic renewal.
• · FTSE is a UK-based company, experienced in digital asset indices, and unaffiliated with the sponsor.
• · The termination and transition are described as a broader move to a new benchmark provider.

07-07-2026

Ark 21Shares Bitcoin ETF (ARKB) announced the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks Ltd., effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change in benchmark provider does not involve any financial figures or performance metrics, but represents a material operational shift for the ETF.

• · The Pricing Benchmark Licensing Agreement had a one-year initial term with automatic renewal for successive one-year periods.
• · CF Benchmarks is unaffiliated with the Sponsor.
• · FTSE is a company incorporated in England with principal offices in London.
• · FTSE is experienced in calculating and administering digital asset indices and is unaffiliated with the Sponsor.
• · The new FTSE license is expected to have a one-year initial term with automatic renewal.

07-07-2026

Suncrete, Inc. (RMIX) subsidiary Concrete Partners, LLC entered into a Fifth Amendment to its Credit Agreement with Bank of America as Administrative Agent, increasing the revolving facility by $25M and establishing a new $175M delayed draw term loan facility. The amendment also adds Wells Fargo and Regions Bank as new lenders. The company must maintain a Consolidated Senior Net Leverage Ratio no greater than 3.75:1.00 and at least $10M in available revolving loans after giving effect to the amendment.

• · The amendment is dated June 30, 2026 and was filed on July 7, 2026.
• · The Credit Agreement was originally dated July 29, 2024 and has been amended four times prior to this Fifth Amendment.
• · The amendment adds Wells Fargo Bank, N.A. and Regions Bank as new Lenders.
• · Conditions for effectiveness include no Material Adverse Effect since December 31, 2025 and a Solvency Certificate from the Borrower.

07-07-2026

21Shares XRP ETF (TOXR) announced the termination of its Pricing Benchmark Licensing Agreement with CF Benchmarks, effective August 31, 2026, as part of a transition to a new benchmark provider. The sponsor intends to enter into a licensing agreement with FTSE International Limited on or about August 24, 2026, to use FTSE index data for valuation and NAV calculation. This change does not involve any financial impact or performance metrics.

• · The Pricing Benchmark Licensing Agreement has a one-year initial term and auto-renews unless terminated.
• · The new FTSE licensing agreement is expected to have a one-year initial term with automatic renewal.
• · CF Benchmarks and FTSE are both unaffiliated with the Sponsor.
• · The termination notice was provided on June 30, 2026, with an effective date of August 31, 2026.

07-07-2026

Intapp, Inc. entered into a Third Amended and Restated Registration Rights Agreement with investors Anderson Investments Pte. Ltd. and Aranda Investments Pte. Ltd., as well as Director John Hall, on July 1, 2026. The agreement extends the term of registration rights until the investors hold less than 5% of outstanding common stock and adds Aranda Investments as a party. The existing material terms remain substantially unchanged from the prior agreement.

• · The Third A&R Registration Rights Agreement amends and restates the Second Amended and Restated Registration Rights Agreement dated July 2, 2021.
• · The agreement extends the term until the Investor holds less than 5% of outstanding common stock.

07-07-2026

Unitil Corporation completed the purchase of two New Hampshire water companies (Aquarion Water Company of NH and Abenaki Water Co.) from Aquarion Water Authority for $55.8 million, including $13.7 million in assumed debt and $0.6 million for working capital. The acquisition adds approximately 11,000 water customers and 150 miles of water mains, expanding Unitil's regulated utility services. The deal is expected to be earnings accretive over the long term, supporting Unitil's 5% to 7% EPS growth target, though integration risks and water-related operational hazards remain.

• · The Stock Purchase Agreement was first announced on May 6, 2025 and subsequently amended to limit the purchase to the two Aquarion Companies.
• · All conditions of the Agreement, including approvals from the New Hampshire and Maine Public Utilities Commissions, were materially completed as of the closing date.
• · Unitil funded the purchase price through a term loan from Scotiabank.
• · The acquired water systems serve eight communities in New Hampshire.
• · Unitil was advised by Scotiabank and the law firm of Dentons.

07-07-2026

Osprey Acquisition Corp. III, a blank check company, priced its $261 million initial public offering of 26.1 million units at $10.00 per unit, with units trading on Nasdaq under the symbol OSPRU starting July 1, 2026. The SPAC will focus on acquiring companies deploying disruptive technologies in energy systems, AI-driven optimization, and sustainable infrastructure. The offering is led by Cantor Fitzgerald & Co., with a 45-day over-allotment option for up to 3.915 million additional units.

• · The Company is a blank check company formed for the purpose of effecting a merger or similar business combination.
• · Primary focus is on companies deploying disruptive technologies in energy systems, AI-driven optimization, and sustainable infrastructure.
• · Units will begin trading on July 1, 2026 under the symbol OSPRU.
• · Class A ordinary shares and warrants are expected to trade separately under symbols OSPR and OSPRW, respectively.
• · Closing of the offering is anticipated on or about July 2, 2026.
• · No fractional warrants will be issued; only whole warrants will trade.

07-07-2026

Lifeward Ltd. entered into a Securities Purchase Agreement dated June 30, 2026, with multiple purchasers and Oramed Pharmaceuticals Inc. as collateral agent, providing for the issuance and sale of Senior Secured Convertible Notes and Ordinary Share purchase warrants in a private placement exempt from registration under the Securities Act. The company will use net proceeds for working capital, general corporate purposes, commercialization efforts, and R&D, and has agreed to indemnify purchasers against certain losses. No specific dollar amounts or share counts are disclosed in this excerpt.

• · The Additional Warrants are exercisable immediately upon issuance and have a term of five years from the date of issuance.
• · The agreement includes a covenant that the Company will not provide material non-public information to purchasers without prior written consent, and any such information inadvertently provided does not impose a duty of confidentiality.
• · The Company is restricted from using proceeds for debt satisfaction (other than the Notes or ordinary trade payables), share redemptions, litigation settlements, or in violation of FCPA or OFAC regulations.
• · The Company has agreed to indemnify Purchaser Parties for losses arising from breaches of representations, warranties, or covenants, as well as certain securities law violations.

07-07-2026

XMax Inc. entered into Securities Purchase Agreements on July 1, 2026, to sell 434,600 shares of common stock at $8.454 per share in a private placement, raising approximately $3.67 million. The shares are subject to an 18-month lock-up period, and the offering was conducted under Regulation S exemption for non-U.S. investors. The filing does not disclose any financial performance metrics, so no positive or negative trends can be assessed.

• · The purchase price per share was $8.454.
• · The lock-up period is 18 months from July 1, 2026.
• · The offering was exempt from registration under Regulation S of the Securities Act of 1933.
• · The filing includes a form of Securities Purchase Agreement as Exhibit 10.1.

07-07-2026

21Shares Ethereum ETF (TETH) disclosed the termination of its pricing benchmark licensing agreement with CF Benchmarks, effective August 31, 2026, as part of a planned transition to a new benchmark provider. The sponsor intends to enter a licensing agreement with FTSE International Limited around August 24, 2026, to use FTSE index data for valuing the Trust's shares and calculating net asset value. The change is a strategic operational shift with no immediate financial impact disclosed.

• · The Pricing Benchmark Licensing Agreement with CF Benchmarks had a one-year initial term with automatic renewal.
• · The new FTSE licensing agreement is expected to have a one-year initial term and auto-renew.
• · FTSE is based in London, UK, and is unaffiliated with the Sponsor.
• · The Trust's shares trade on Cboe BZX Exchange under ticker TETH.
• · The registrant is an emerging growth company and has not elected to use the extended transition period for new financial accounting standards.

07-07-2026

MacroGenics completed the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals for $122.5 million in cash, before transaction fees and expenses. The deal includes the transfer of facilities in Rockville and Frederick, Maryland, and approximately 140 former MacroGenics employees hired by Bora. MacroGenics has entered into a supply agreement with Bora to support its internal pipeline needs, but the company remains a clinical-stage biopharmaceutical firm with no mention of immediate revenue growth from this transaction.

• · MacroGenics' manufacturing site in Rockville, Maryland, and warehouse in Frederick, Maryland, have been transferred to Bora.
• · MacroGenics entered into a supply agreement with Bora for process development and drug substance production for its internal pipeline.
• · Moelis & Company LLC served as exclusive financial advisor to MacroGenics; Sidley Austin LLP and Covington & Burling served as legal counsel.
• · Jones Day served as legal counsel to Bora.
• · The filing includes cautionary forward-looking statements regarding risks related to post-closing manufacturing arrangements and the possibility that additional post-closing cash payments may not be earned or received.

07-07-2026

Primo Brands Corp announced the elimination of the Chief Operating Officer position effective July 7, 2026, with Robert Austin transitioning out of the role and remaining employed through December 31, 2026. CEO Eric Foss will assume the principal operating officer duties. The company will not hire a replacement for the COO role, and Mr. Austin will receive separation benefits, continued equity vesting, accelerated vesting of Class B Units, and a supplemental payment of $330,000.

• · The Board determined to eliminate the COO position on July 2, 2026, effective July 7, 2026.
• · Robert Austin will remain employed as COO through December 31, 2026 to support transition.
• · No replacement will be hired for the COO role.
• · Mr. Austin will receive separation pay per the Primo Brands Corporation Severance and Non-Competition Plan, modified by his December 11, 2024 offer letter.
• · Equity treatment will follow the Primo Brands Equity Incentive Plan and award agreements.
• · Mr. Austin will receive continued vesting of the final tranche of his time-vesting RSU award granted December 2024 and continued eligibility for performance-vesting RSUs granted December 2024.
• · Mr. Austin will receive accelerated vesting of all his Class B Units in Triton Water Parent Holdings, LP.

07-07-2026

Interactive Strength Inc. (TRNR) entered into a Settlement Agreement with Vertical Investors, LLC on June 30, 2026, issuing 225,681 shares of Series C Preferred Stock as payment for a $451,361 Net Trade Value owed under a prior Loan Restoration Agreement. The settlement resolves a shortfall where the Total Loan Exchanged Amount of approximately $9,034,431 far exceeded the Net Trade Value of $451,361, highlighting the company's ongoing financial strain and reliance on equity-based settlements.

• · The Settlement Agreement was entered into on June 30, 2026, and filed on July 7, 2026.
• · The original Credit Agreement was dated February 1, 2024, with a principal amount of $7,968,977.74.
• · On March 29, 2024, 1,500,000 shares of Series A Preferred Stock were issued upon conversion of $3.0 million of the loan.
• · The Loan Modification Agreement on April 24, 2024 reduced the principal by $3.0 million.
• · The Loan Restoration Agreement required the company to pay any shortfall if Net Trade Value was less than Total Loan Exchanged Amount by December 31, 2025.
• · The Net Trade Value of $451,361 represents only about 5% of the Total Loan Exchanged Amount of $9,034,431.
• · The issuance of Series C Preferred Shares was exempt from registration under Section 4(a)(2) of the Securities Act.

07-07-2026

T-Mobile announced the appointment of Chris Sambar as Chief Enterprise Officer, effective no later than October 14, 2026, and expanded André Almeida's role to Chief Marketing, Brand & Broadband Officer. The leadership changes aim to accelerate growth in enterprise, broadband, and emerging areas like T-Ads and Physical AI, while Mike Katz steps down as Chief Business & Product Officer and will remain in an advisory role through December 2026. The filing does not include financial results, so no period-over-period comparisons are available.

• · Chris Sambar joins from Public Storage, where he was COO, and previously spent two decades at AT&T, including as President, Network.
• · Mike Katz will remain in a strategic advisory role through December 2026 to support transition.
• · T-Mobile's network, technology, product engineering and cyber will be integrated under CTO Dr. John Saw.
• · The leadership evolution aligns with strategic priorities outlined in the February 2026 Capital Markets Update.

07-07-2026

Global Industrial Company (GIC) entered into Amendment No. 4 to its Third Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A. as Administrative Agent, dated June 30, 2026. The amendment modifies certain terms, schedules, and exhibits of the credit agreement and includes post-effective date covenants requiring corrective patent filings and good standing certificates for certain subsidiaries. No financial amounts or changes to credit limits were disclosed in the filing.

• · The amendment requires corrective filings with the USPTO within 30 days to fix a prior patent assignment error where patents owned by Global Industrial Distribution Inc. were erroneously recorded as owned by Global Equipment Company Inc.
• · Within 90 days, the company must use commercially reasonable efforts to obtain certificates of good standing for Indoff Holdings Inc. (Illinois and North Dakota) and Global Industrial Services, Inc. (Wisconsin and Oklahoma), and release all existing tax liens.
• · The amendment restates and reaffirms all representations and warranties of the loan parties as true and correct, with no Default or Event of Default continuing after giving effect to the amendment.
• · The amendment was executed by Thomas Clark on behalf of all borrower and guarantor entities.

07-07-2026

NextNRG, Inc. entered into a $1.0M (net $940K after $60K fee) Merchant Cash Advance agreement with Avanza Capital Holdings. The deal provides immediate liquidity against $1.5M of future receivables but carries a 25% daily settlement lock-up and 25% liquidated damages on defaults. While the financing alleviates near-term cash constraints, the high effective cost and CEO Michael Farkas's personal guarantee underscore significant credit risk.

• · Agreement is secured by a first priority security interest in all of the Company's present and future accounts, deposit accounts, accounts receivable, chattel paper, documents, equipment, general intangibles, instruments, inventory, and proceeds.
• · CEO Michael D. Farkas personally guaranteed the full performance of all representations, warranties, and covenants under the Avanza MCA.
• · Upon default, Avanza may declare the full uncollected Receivables Purchased Amount plus all fees immediately due and payable, and collect 25% of the unpaid balance as liquidated damages.
• · The Company may prepay the outstanding balance at any time without penalty.

07-07-2026

Public Storage announced that COO Chris Sambar resigned effective end of July 2026 to join T-Mobile as Chief Enterprise Officer; the resignation was not related to any disagreement with the company. Operations leadership will report directly to CEO Tom Boyle until a permanent replacement is found, as the company continues its PS4.0 strategic vision and integration of recent acquisitions.

• · Chris Sambar's resignation is effective at the end of July 2026.
• · He is leaving to become Chief Enterprise Officer at T-Mobile.
• · The resignation was not due to any disagreement with Public Storage's operations, policies, or practices.
• · Operations leadership team will report directly to CEO Tom Boyle until a permanent COO replacement is identified.
• · The company references its PS4.0 strategic vision and planned integrations of recently announced acquisitions.